Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume Increase

Centessa Pharmaceuticals plc (NASDAQ:CNTA) saw unusually-strong trading volume on Wednesday . Approximately 625,600 shares were traded during trading, an increase of 78% from the previous session’s volume of 352,390 shares.The stock last traded at $9.02 and had previously closed at $9.40.

Wall Street Analysts Forecast Growth

Separately, BMO Capital Markets reiterated an “outperform” rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a research note on Monday, April 1st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Centessa Pharmaceuticals Stock Performance

The business’s fifty day moving average price is $10.95 and its two-hundred day moving average price is $8.50. The company has a quick ratio of 8.00, a current ratio of 8.00 and a debt-to-equity ratio of 0.32.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. The firm had revenue of $6.85 million for the quarter. On average, equities analysts forecast that Centessa Pharmaceuticals plc will post -1.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 51,160 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the completion of the sale, the insider now owns 71,525 shares of the company’s stock, valued at approximately $849,717. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Karen M. Anderson sold 51,160 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total transaction of $607,780.80. Following the completion of the transaction, the insider now owns 71,525 shares in the company, valued at approximately $849,717. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Harris Rotman sold 4,267 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.10, for a total transaction of $34,562.70. Following the transaction, the senior vice president now owns 62,625 shares of the company’s stock, valued at approximately $507,262.50. The disclosure for this sale can be found here. 11.54% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CNTA. TD Asset Management Inc increased its stake in Centessa Pharmaceuticals by 127.1% during the 3rd quarter. TD Asset Management Inc now owns 186,310 shares of the company’s stock valued at $1,205,000 after purchasing an additional 104,255 shares in the last quarter. Platinum Investment Management Ltd. increased its stake in Centessa Pharmaceuticals by 96.7% during the 3rd quarter. Platinum Investment Management Ltd. now owns 337,544 shares of the company’s stock valued at $2,184,000 after purchasing an additional 165,919 shares in the last quarter. Rathbones Group PLC acquired a new position in Centessa Pharmaceuticals during the 3rd quarter valued at approximately $203,000. Affinity Asset Advisors LLC increased its stake in Centessa Pharmaceuticals by 13.0% during the 3rd quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company’s stock valued at $6,587,000 after purchasing an additional 117,368 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its stake in Centessa Pharmaceuticals by 25.8% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock valued at $18,313,000 after purchasing an additional 580,500 shares in the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.